What are the key takeaways from this The Readout Loud episode?

Key insights include: **M&A Timing Strategy:** The Gilead-Arcellx deal at $7.9B illustrates that acquisitions of co-development partners carry minimal surprise risk for investors. Gilead already held equity in Arcellx and manufactured their CAR-T therapy through KITE. Deals structured around existing partnerships signal lower integration risk and tend to be priced in by markets well before announcement, making timing the only real variable.; **FDA Regulatory Inconsistency Risk:** Companies developing rare disease therapies face a specific investment hazard: FDA guidance can reverse between application cycles. Atara Biotherapeutics resolved manufacturing issues over a year per FDA direction, then received new clinical deficiencies upon resubmission. Investors like RTW's Rod Wong are actively reducing rare disease exposure specifically because the regulatory pathway shifts unpredictably between review teams.; **Obesity Drug Valuation Divergence:** Since 2021, Eli Lilly shares have risen approximately 450-500% while Novo Nordisk shares remain essentially flat, despite both Zepbound and Wegovy delivering comparable 15-20% body weight reduction outcomes. Novo's aggressive price-cutting strategy to recapture market share has compressed pricing across the duopoly faster than anticipated, with prices already halved within roughly two and a half years of launch.

What did Jared Holtz discuss on The Readout Loud?

Adam Feuerstein and Mizuho Securities analyst Jared Holtz assess biotech sector conditions in early 2026, covering the Gilead-Arcellx $7.9B acquisition, FDA regulatory inconsistencies affecting rare disease drugs, the widening Eli Lilly versus Novo Nordisk valuation gap, midterm election implications for drug pricing, and AI's potential disruption of the industry. Key topics include: **M&A Timing Strategy:** The Gilead-Arcellx deal at $7.9B illustrates that acquisitions of co-development partners carry minimal surprise risk for investors. Gilead already held equity in Arcellx and manufactured their CAR-T therapy through KITE. Deals structured around existing partnerships signal lower integration risk and tend to be priced in by markets well before announcement, making timing the only real variable.; **FDA Regulatory Inconsistency Risk:** Companies developing rare disease therapies face a specific investment hazard: FDA guidance can reverse between application cycles. Atara Biotherapeutics resolved manufacturing issues over a year per FDA direction, then received new clinical deficiencies upon resubmission. Investors like RTW's Rod Wong are actively reducing rare disease exposure specifically because the regulatory pathway shifts unpredictably between review teams..

How long is this episode of The Readout Loud?

This episode is 32 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Readout Loud

390: FDA turmoil, election intrigue, AI, and more

February 26, 2026

32 min episode · 2 min read

Jared Holtz

Episode

32 min

Read time

2 min

Topics

Productivity, Relationships, Investing

AI-Generated Summary

Published Feb 27, 2026

Key Takeaways

✓M&A Timing Strategy: The Gilead-Arcellx deal at $7.9B illustrates that acquisitions of co-development partners carry minimal surprise risk for investors. Gilead already held equity in Arcellx and manufactured their CAR-T therapy through KITE. Deals structured around existing partnerships signal lower integration risk and tend to be priced in by markets well before announcement, making timing the only real variable.
✓FDA Regulatory Inconsistency Risk: Companies developing rare disease therapies face a specific investment hazard: FDA guidance can reverse between application cycles. Atara Biotherapeutics resolved manufacturing issues over a year per FDA direction, then received new clinical deficiencies upon resubmission. Investors like RTW's Rod Wong are actively reducing rare disease exposure specifically because the regulatory pathway shifts unpredictably between review teams.
✓Obesity Drug Valuation Divergence: Since 2021, Eli Lilly shares have risen approximately 450-500% while Novo Nordisk shares remain essentially flat, despite both Zepbound and Wegovy delivering comparable 15-20% body weight reduction outcomes. Novo's aggressive price-cutting strategy to recapture market share has compressed pricing across the duopoly faster than anticipated, with prices already halved within roughly two and a half years of launch.
✓Biotech Sector Volatility Pattern: Despite biotech indices trading near recent highs in early 2026, daily individual stock moves of 3-5% have become routine, a pattern not seen in prior years. Investors are buying on weakness even after negative clinical data, driven by M&A speculation and short-covering. This creates a floor under beaten-down names but also signals elevated day-to-day risk for position sizing.
✓Political Scenario Planning for Pharma: Midterm elections shifting House control to Democrats are unlikely to meaningfully reverse existing drug pricing agreements, as pharmaceutical stocks have already priced in current arrangements. However, RFK Jr.'s potential 2028 presidential run could trigger HHS leadership turnover by 2027, and any departure of FDA leadership figures like Vinay Prasad would likely produce an immediate positive sector re-rating.

What It Covers

Adam Feuerstein and Mizuho Securities analyst Jared Holtz assess biotech sector conditions in early 2026, covering the Gilead-Arcellx $7.9B acquisition, FDA regulatory inconsistencies affecting rare disease drugs, the widening Eli Lilly versus Novo Nordisk valuation gap, midterm election implications for drug pricing, and AI's potential disruption of the industry.

Key Questions Answered

•M&A Timing Strategy: The Gilead-Arcellx deal at $7.9B illustrates that acquisitions of co-development partners carry minimal surprise risk for investors. Gilead already held equity in Arcellx and manufactured their CAR-T therapy through KITE. Deals structured around existing partnerships signal lower integration risk and tend to be priced in by markets well before announcement, making timing the only real variable.
•FDA Regulatory Inconsistency Risk: Companies developing rare disease therapies face a specific investment hazard: FDA guidance can reverse between application cycles. Atara Biotherapeutics resolved manufacturing issues over a year per FDA direction, then received new clinical deficiencies upon resubmission. Investors like RTW's Rod Wong are actively reducing rare disease exposure specifically because the regulatory pathway shifts unpredictably between review teams.
•Obesity Drug Valuation Divergence: Since 2021, Eli Lilly shares have risen approximately 450-500% while Novo Nordisk shares remain essentially flat, despite both Zepbound and Wegovy delivering comparable 15-20% body weight reduction outcomes. Novo's aggressive price-cutting strategy to recapture market share has compressed pricing across the duopoly faster than anticipated, with prices already halved within roughly two and a half years of launch.
•Biotech Sector Volatility Pattern: Despite biotech indices trading near recent highs in early 2026, daily individual stock moves of 3-5% have become routine, a pattern not seen in prior years. Investors are buying on weakness even after negative clinical data, driven by M&A speculation and short-covering. This creates a floor under beaten-down names but also signals elevated day-to-day risk for position sizing.
•Political Scenario Planning for Pharma: Midterm elections shifting House control to Democrats are unlikely to meaningfully reverse existing drug pricing agreements, as pharmaceutical stocks have already priced in current arrangements. However, RFK Jr.'s potential 2028 presidential run could trigger HHS leadership turnover by 2027, and any departure of FDA leadership figures like Vinay Prasad would likely produce an immediate positive sector re-rating.

Notable Moment

FDA Commissioner Marty Makari described on CNBC a therapy requiring surgical skull drilling that showed no benefit in randomized trials yet faced approval pressure. Though unnamed, markets identified the description as UniCure's Huntington's disease program, sending the stock down approximately 30% within the same trading session.

Know someone who'd find this useful?

Episode Transcript

Welcome to this week's episode of the Read Out Loud, a weekly biotech podcast from STAT. I'm Adam Feuerstein. It's Thursday, February 26, and, I'm here alone. My usual cohost, Allison DeAngelis and Elaine Chen, are taking some time off this week. You know, I thought about recording this episode by myself, but then I also thought, do our dear cherished listeners really wanna hear me drone on for thirty minutes? Probably not. Thankfully, I found some help. Jared Holtz, health care sector specialist at Mizuho Securities and a dear friend of mine, agreed to be my podcasting wingman for the week. Jared will join me to share some hot takes on biotech in a moment, but first, a word from our sponsor. Science doesn't stop at your job description, and neither should your curiosity. New Scientist brings you stories that reach beyond the day to day and into the discoveries shaping our future. Whether you're at work or simply in need of inspiration, there's always more to explore and more to enjoy. With trusted journalism since 1956, New Scientist gives you a place to escape, think bigger, and follow your curiosity welcome back welcome back to the read out loud in in the cohost chair this week. Hey, Adam. Thanks so much for having me. Yeah. This is very cool, so I I appreciate it. I mean, this could be the start of something. You know? We we might have, like, the next Joe Rogan. You know? I like it. Let's keep it going. So, let's start off. You know, Jared, you keep an eye on all things health care, and obviously, we, you know, we focus here on this podcast on biotech and pharma. But, you know, just kinda generally, like, how are you feeling and and what's your take on kind of the sector so far? You know, we're, you know, almost two months into the year. Yeah. It it feel things feel pretty good to me. You know, obviously, there are still a number of controversies that, surround biotech and pharma and and always will. But I I think the trading action so far has been pretty encouraging, especially since, you know, we sort of came into the year on the biotech side, anticipating, you know, a real flurry of m and a activity, and there was some speculation towards the end of the year. It's been, you know, perhaps a little bit slower than than the street thought. I think all things considered, to see the index at, you know, recent highs is is pretty encouraging, and, obviously, large cap pharma have traded well. I think sometimes you need the leadership, the larger companies to to act well in order for small and mid cap to sort of follow suit. So that's sort of what we've gotten so far. Yeah. You know, my my my take on it or my feeling is that if we if we think back to, like, a year ago, Jared, …

Get the full transcript (5,735 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Readout Loud transcripts →